Beijing Airdoc Technology Co., Ltd. focuses on the provision of artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, Airdoc-AIFUNDUS, which is an AI-assisted diagnosis of retinal detection product that is available in three versions comprising version 1.0 for the diagnosis of diabetic retinopathy, version 2.0 that address a wide range of fundus diseases, and version 3.0 for the diagnosis of pathological myopia and retinal detachment. It also provides the AI-FUNDUSCAMERA-P, a series of portable automatic, and self-service fundus cameras that allow retinal mages capture without specialized operators; the AI-FUNDUSCAMERA-M, a multimodal health scanner that integrates a variety of biosensors and supports a number of health detection functions; and the AI-FUNDUSCAMERA-D, a fully automatic and self-service desktop fundus camera. The company also provides health risk assessment solutions to detect risk indicators, such as retinal abnormalities, retinal vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. In addition, the company develops SaMD products for glaucoma and cataracts detection; an AI-driven integrated myopia intervention solutions, including the PBM LED myopia therapy device; and an AI-based visual training product for the treatment of strabismus and amblyopia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People's Republic of China.